Advertisement

Topics

Gilteritinib, a FLT3 inhibitor, shows promise in relapsed leukaemia

10:26 EDT 22 Jun 2017 | ecancermedicalscience

A new drug shows promise in its ability to target one of the most common and sinister mutations of acute myeloid leukaemia (AML), according to researchers at the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer...

Original Article: Gilteritinib, a FLT3 inhibitor, shows promise in relapsed leukaemia

NEXT ARTICLE

More From BioPortfolio on "Gilteritinib, a FLT3 inhibitor, shows promise in relapsed leukaemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...